In 2020, Montemurro et al. published data from a subgroup of 398 patients with BM from the KAMILLA trial, a single-arm phase IIIb study of T-DM1 in patients with HER2-positive locally advanced/metastatic BC. Here, ERBB2 is linked to breast cancer.